Introduction
Acetylcholine (ACh) plays vital roles as a neurotransmitter in modulating diverse central functions such as sleep, alertness, cognition, motor control, sensory processing, learning, and memory. There are two major families of receptors for ACh, the ionotropic nicotinic and metabotropic muscarinic receptors, and physiological functions of ACh are predominantly mediated through the latter in the central nervous system. The muscarinic ACh receptor (mAChR) family consists of five receptor subtypes termed M 1 -M 5 , which are further separated into two groups based on G-protein coupling. The first group (M 1 , M 3 , and M 5 mAChRs) activate phospholipase C and mobilize intracellular calcium through G q/11 , while the second group (M 2 and M 4 mAChRs) are coupled to G i/o and inhibit adenylate cyclase activity (1, 2) .
An initial and common signaling step for G-proteincoupled receptors (GPCRs) including mAChRs is the agonist-induced binding of GTP to Ga subunits, and this step, utilizing slowly hydrolysable guanosine-5′-O-(3 -[ 35 S]thio)triphosphate ([ 35 S]GTPgS), has been frequently used for investigations of receptor-ligand interactions (3) . In general, this assay is experimentally more feasible for receptors coupled to the abundant G i/o proteins. As described above, the M 2 and M 4 receptors are known to be coupled to G i/o proteins, thus making the [ 35 S]GTPgS binding assay a good candidate with which to study the pharmacological properties of these receptors. Due to overlapping expression profiles in the brain and lack of highly selective ligands for each mAChR subtypes, however, the pharmacological characteristics of the endogenously expressed M 2 and M 4 mAChRs have been poorly understood in native tissue to date.
Recently, Chapman et al. (4) reported that carbachol (CCh) stimulated specific [ 35 S]GTPgS binding in striatal membranes in M 2 mAChR-knockout mice as well as wild type, but not in M 4 mAChR-knockout mice, clearly indicating that M 4 mAChR was a predominant functional receptor subtype. They also utilized compound 28 (5), a selective M 4 mAChR antagonist, and concluded that CCh-stimulated [ 35 S]GTPgS binding in rat striatum was mediated through the M 4 mAChR subtype. As mentioned by themselves, however, it is far from satisfactory enough to use only one compound to characterize definitely a pharmacological response. It is also unknown whether this response can be extended to brain regions other than the striatum. In the present study, we determined mAChR-mediated [ 35 S]GTPgS binding not only in rat striatum, but also in the cerebral cortex and hippo campus, with the help of a number of mAChR-related ligands.
Materials and Methods

Materials
[ ,4] benzodiazepin-6-one (AF-DX 116), 3,6a,11,14-tetrahydro-9-methoxy-2-methyl-(12H)-isoquino [1,2-b] pyrrolo [3,2- 
Membrane preparation
The experimental protocols were reviewed and approved by the Animal Committee of Saitama Medical University, and the animal care and use procedures conformed to the Guiding Principles approved by The Japanese Pharmacological Society. Male SpragueDawley rats weighing 200 -250 g were killed by decapitation and their brains were quickly removed. The cerebral cortex, hippocampus, or striatum, dissected from each rat, was homogenized in 5 ml of ice-cold TED buffer (5 mM Tris-HCl, 1 mM EDTA, 1 mM dithiothreitol, pH 7.4) containing 10% (w/v) sucrose by 20 strokes with a motor-driven Teflon/glass tissue grinder. All the following centrifuge procedures were carried out at 4°C. Subsequent to centrifugation of the homogenate at 1,000 × g for 10 min, the supernatant was decanted to another centrifuge tube. The pellet was vortexed in 5 ml of TED/sucrose buffer and centrifuged again at 1,000 × g for 10 min. The combined supernatant (10 ml) was centrifuged at 9,000 × g for 20 min and resuspended in 10 ml of TED buffer. After the same procedure was repeated, the homogenate was kept on ice for 30 min, followed by the final centrifugation at 35,000 × g for 10 min. The resulting pellet was resuspended in 50 mM Tris-HCl buffer (pH 7.4) to produce the homogenate with a protein concentration ranging from 1.0 to 2.0 mg/ml. The homogenate was frozen quickly on fine-grained dry ice and stored at −80°C until use.
[ 35 S]GTPgS binding
The activation of specific [ 35 S]GTPgS binding to rat brain membranes mediated by mAChRs was determined as described previously (6) . In brief, the brain membranes equivalent to 10 -20 mg protein were incubated in duplicate at 30°C for 60 min in 500 ml of 50 mM Tris-HCl buffer (pH 7.4) containing 0.2 nM [ 35 S]GTPgS, 20 mM GDP, 5 mM MgCl 2 , 0.1 mM EDTA, 0.2 mM ethylene glycolbis(2-aminoethylether)-N,N,N,N-tetraacetic acid (EGTA), 0.2 mM dithiothreitol, 100 mM NaCl, and various concentrations of cholinergic ligands. After the incubation, the homogenate was filtered under vacuum through glass fiber filters (GF/B; Whatman International, Kent, UK) using a Brandel cell harvester with 2 × 5 ml washing with ice-cold 50 mM Tris-HCl buffer (pH 7.4), and the radioactivity content retained on the filter was counted in 8 ml scintillation cocktail EmulsifierScintillator Plus (Packard Bioscience; Meriden, CT, USA) by a liquid scintillation counter. The non-specific binding was measured in the presence of 100 mM unlabeled GTPgS, which was subtracted from the total binding to define the specific [ 35 S]GTPgS binding.
Data analysis
All results were presented as the mean ± S.E.M. of the indicated number of separate experiments, each performed in duplicate. The concentration-dependent increases in specific [ 35 S]GTPgS binding by CCh and ACh were expressed as the percentage increase over the basal unstimulated value and analyzed using a nonlinear regression method with GraphPad Prism (GraphPad Software; La Jolla, CA, USA), to produce the concentration eliciting the half-maximal effect (EC 50 ) and the maximal percentage increase (%E max ). In the case of other mAChR agonists, the increases in specific [
35 S] GTPgS binding over the basal unstimulated value were normalized with the increase elicited by 10 mM CCh regarded as 100%, and analyzed as well. The inhibition curve for mAChR antagonists against 100 mM CCh was also analyzed by a nonlinear regression method, with the basal and the CCh-stimulated binding regarded as 0% and 100%, respectively, to generate the concentration that inhibited the binding to 50% (IC 50 ).
Results
Effects of mAChR agonists
As shown in Fig. 1 In the following experiments using mAChR agonists, the increase in specific [ 35 S]GTPgS binding elicited by 10 mM CCh was always measured in parallel, and the increase in specific binding by the test compound was expressed as a normalized value, as exemplified in Fig. 2 . Nonlinear regression analysis of the concentration-response curve for each compound yielded varied EC 50 values and normalized %E max values, as listed in Table 1 . In addition to the compounds conventionally classified as mAChR agonists, xanomeline, and Ndesmethylclozapine were included in the present study, following the previous report (4) .
Effects of mAChR antagonists on CCh-stimulated [ 35 S]GTPgS binding
The inhibitory effects of a series of mAChR antagonists on CCh-stimulated [ Table 2 . An exception was the inhibitory curve of J 104129 in hippocampal membranes, which was extraordinarily shallow and apparently biphasic ( Correlation of pEC 50 and pIC 50 values
The rank order of potencies of mAChR agonists (Table 1 ) and antagonists (Table 2 ) determined in the present study appeared very similar regardless of the brain regions. When the pEC 50 and pIC 50 values determined in the hippocampus were compared with those in the striatum (Fig. 5A ), there was a highly significant correlation with a correlation coefficient of 0.95 and a slope of 0.95 (P < 0.001). Likewise, highly significant correlations between the cerebral cortex and striatum (r = 0.94, P < 0.001) (Fig. 5B ) and between the cerebral cortex and hippocampus (r = 0.93, P < 0.001) (Fig. 5C ) were obtained. In these comparisons, J 104129 was excluded because of its unique agonistic properties in 
Not determinable because of low efficacy. Values are presented as the mean ± S.E.M. of 4 -6 separate experiments. the hippocampus, as described above. Also, xanomeline and N-desmethylclozapine were omitted, since the agonistic effects of these compounds in rat brain membranes were, at least in part, derived from the mechanisms involving receptors other than mAChRs, as commented in detail in the Discussion. The pEC 50 and pIC 50 values for a series of mAChR ligands in the cerebral cortex determined in the present study were also correlated with those determined by means of antibody-capture scintillation proximity assay (SPA)/[
35 S]GTPgS binding using anti-Ga q antibody in the same brain region (Fig. 5D) . As reported recently (7), M 1 mAChR-mediated activation of Ga q is detectable by this method. Although still significant (P < 0.001), the correlation coefficient (0.80) was much lower than those described above. Furthermore, the slope of the regression line was 0.39, far from unity.
Effects of muscarinic toxins on CCh-stimulated [
S]GTPgS binding
Muscarinic toxins serve as useful probes in mAChR research (8) . As shown in Fig. 6 , the increase in specific 
S]GTPgS binding with anti-Gaq antibody, the method for functional activation of Gaq coupled with M1 mAChR (7). mAChR/G-Protein Coupling in Rat Brain
The %E max value was unaltered (36.6% ± 1.3% and 35.3% ± 1.2% in the absence and presence of 1 mM MT3, respectively; n = 3, P > 0.05, paired Student's t-test), while the EC 50 value of CCh was significantly (P < 0.01) increased from 5.05 mM (pEC 50 = 5.30 ± 0.03) to 48.8 mM (pEC 50 = 4.31 ± 0.08) and the Hill slope was significantly (P < 0.01) reduced from 1.07 ± 0.08 to 0.54 ± 0.03 by the addition of 1 mM MT3.
Effects of M 4 mAChR allosteric modulators on CChstimulated [
S]GTPgS binding
The concentration-response curves for CCh were then determined in the absence and presence of the compounds that had been reported to act as allosteric modulators of M 4 mAChRs, i.e., VU 10010 (9), thiochrome (10), and brucine N-oxide (11) . As shown in Fig. 7A , the addition of increasing concentrations of VU 10010 shifted the curve leftwards as well as upwards in rat striatal membranes. The EC 50 value was shifted from 9.40 mM in the absence of VU 10010 (pEC 50 = 5.03 ± 0.02) to 3.63 mM (pEC 50 = 5.44 ± 0.06) and 2.11 mM (pEC 50 = 5.68 ± 0.02) in the presence of 1 and 10 mM VU 10010, respectively (P < 0.001, one-way repeated measures ANOVA). The %E max value in the absence of VU 10010 (102.6 ± 2.2) was increased significantly (P < 0.01) to 116.4 ± 6.1 and 130.2 ± 6.0 in the presence of 1 and 10 mM VU 10010, respectively. The similar results were obtained also in rat cerebral cortical membranes (data not shown). On the other hand, the addition of neither thiochrome (10 and 100 mM) (Fig. 7B) 
Interaction between mAChR-and 5-HT 1A receptormediated G-protein activation
We previously showed that 5-HT-stimulated [
35 S]GTPgS binding in rat cerebral cortical membranes was mediated through 5-HT 1A receptors (12) . In the present study, the increase in specific [ 35 S]GTPgS binding elicited by CCh was determined in the absence and presence of 5-HT at a maximally effective concentration, 100 mM (Fig. 8) .
In the absence of 5-HT, CCh stimulated the specific [
35 S]GTPgS binding with a mean EC 50 of 6.19 mM (pEC 50 = 5.21 ± 0.05) to the %E max value of 37.9% ± 2.0% (n = 4). In the presence of 100 mM 5-HT, the specific binding was increased by 38.9% ± 2.5% and the addition of increasing concentrations of CCh further augmented the binding to 67.3% ± 1.9% with a mean EC 50 of 9.64 mM (pEC 50 = 5.02 ± 0.09). When the percent increase elicited by 100 mM 5-HT and the %E max value determined with CCh alone was simply added in each experiment, the increase by 76.9% ± 1.8% was obtained as the theoretical value on the assumption that both mAChRs and 5-HT 1A receptors stimulated completely distinct pools of G-proteins without any interaction. In fact, there was statistically significant difference among the %E max for CCh alone, the %E max for CCh in the presence of 100 mM 5-HT, and the theoretical additive value (P < 0.001, one-way repeated measures ANOVA).
Although not completely (P < 0.05, Tukey's multiple comparison test, between the measured %E max for CCh in the presence of 100 mM 5-HT and the theoretical additive value), there appeared additive effects between mAChRmediated and 5-HT 1A receptor-mediated G-protein activation (P < 0.001, Tukey's multiple comparison test, between the measured %E max for CCh alone and the measured %E max for CCh in the presence of 100 mM 5-HT).
Discussion
In the current study, we tried to characterize pharmacologically the functional activation of G-proteins coupled to mAChRs detected by means of the conventional [
35 S]GTPgS binding assay in three discrete brain regions of rats. The %E max values determined by using the endo genous ligand ACh as well as the full agonist CCh were the highest in the striatum. Nevertheless, the responses in the cerebral cortex and hippocampus were still enough high to perform further detailed pharmacological investigations. The distribution of mAChR subtypes in the brain has been investigated using several different approaches, i.e., quantitative receptor binding autoradiography, in situ hybridization, and immunohistochemistry. By using immunoprecipitation with subtype selective antibodies, Levy et al. (13) showed that M 1 , M 2 , and M 4 mAChRs are the predominant subtypes expressed in the brain, with M 3 and M 5 mAChRs also being expressed throughout the brain in low abundance. Among five mAChR subtypes, M 2 mAChR immunoreactivity is abundantly expressed in basal forebrain, scattered striatal neurons, mesopontine tegmentum, and cranial motor nuclei, while M 4 mAChR immunoreactivity is enriched in neostriatum, olfactory tubercle, and islands of Calleja (13) . Quantitative immunoprecipitation study demonstrates that of the total mAChRs, M 1 , M 2 , and M 4 mAChR subtypes represent approximately 31%, 29%, and 29%, respectively, in the striatum and 40%, 37%, and 15%, respectively, in the cortex (13) . Vilaró et al. (14) demonstrated that M 4 mRNA was the most abundant, followed by M 1 mRNA, with M 2 and M 3 mRNAs much less abundantly expressed, in rat neostriatum. The highest %E max values for CCh and ACh in the striatum among the three discrete brain regions examined in the present study appear to correspond well to the expression pattern of M 4 mAChR subtype (13) .
The pharmacological profiles investigated with a series of mAChR agonists and antagonists in the three discrete brain regions in the current study are essentially identical to one another, indicating that the same mAChR subtype is involved. As already mentioned in the Introduction, Chapman et al. (4) identified the mAChR involved in CCh-stimulated [ 35 S]GTPgS binding in the striatum as the M 4 subtype, based on the experiments using knockout mouse tissue as well as a selective M 4 mAChR antagonist, compound 28 (5). Although we were unable to include this commercially unavailable compound in the present study, the pharmacological characteristics were not inconsistent with the involvement of M 4 mAChR. However there are a few discrepancies between the results reported by Chapman et al. (4) and ours. The most prominent one is the potency of ACh, which is extraordinarily low (pEC 50 = 3.0 ± 0.09) in the report of Chapman et al. (4) , in comparison with that in our study (pEC 50 = 4.83 ± 0.12). They mentioned the possibility of the presence of endogenous acetylcholinesterase in their sample tissue, and this is likely because they used whole membrane preparation after washing only two times.
In accordance with the report of Chapman et al. (4), we also tested xanomeline and N-desmethylclozapine as agonists in this assay system. Both compounds stimulated the specific [ 35 S]GTPgS binding with submiocromolar to micromolar order EC 50 values in all three brain regions. Surprisingly, the %E max values for both compounds overshot the %E max of the full mAChR agonist CCh in the hippocampus. These results raised doubts about the origin of the stimulatory effects of both compounds. It has been reported that xanomeline behaves as an agonist at 5-HT 1A receptors (15) and that Ndesmethylclozapine acts as an agonist at 5-HT 1A receptors as well as d-opioid receptors (16) . The stimulatory effects of xanomeline and N-desmethylclozapine detected in the present study may include the effects meditated by these G i/o -coupled receptors other than mAChRs. This should be ascertained by the experiments using a series of antagonists against xanomeline-and N-desmethylclozapine-stimulated [ 35 S]GTPgS binding, which are now in progress in our laboratory. At present, it appears problematic to include these two compounds as pure mAChR agonists, and this is the reason we excluded these reagents from the pEC 50 /pIC 50 correlation analyses.
Another compound that was not included in the pEC 50 /pIC 50 correlation analyses was J 104129, the compound reportedly referred to as a selective M 3 mAChR antagonist (17) . Although we are unaware of the reports with regard to its pharmacological properties besides it being an mAChRs antagonist, the present data clearly indicate that J 104129 stimulates specific [
35 S]GTPgS binding in the hippocampus, probably mediated through the receptors that are coupled to G i/o and expressed in abundance especially in this brain area. The pEC 50 and pIC 50 values determined in the present study were still significantly correlated with those determined by antibody-capture SPA/[
35 S]GTPgS binding using an anti-Ga q antibody, which were mediated through M 1 mAChRs (7). This means that most mAChR ligands do not possess high subtype selectivity to discriminate between Ga q -coupled M 1 mAChRs and Ga i/o -coupled mAChR subtype involved in the present study. However, several antagonists showed substantial preference for M 1 mAChRs over the mAChRs of interest in the present study, with > 100-fold selectivity for pirenzepine and > 40-fold selectivity for DAU 5884, scopolamine, and telenzepine. These results appear quite reasonable regarding pirenzepine, DAU 5884, and telenzepine, because it has been reported that these three antagonists show the highest affinities at M 1 mAChR subtype over the other mAChRs (18 -20) . In contrast to these compounds, scopolamine is usually referred to as a nonselective mAChR antagonist, with roughly equivalent affinities to all five mAChR subtypes (19) . However, this result was derived from the experiment using cloned human mAChR subtypes expressed in Chinese hamster ovary (CHO) cells, and it was reported that scopolamine had substantial selectivity to M 1 mAChRs in rat brain (21) . There may be some differences in pharmacological properties of mAChRs between human and rat, as suggested by Van den Beukel et al. (22) .
Currently, there is a lack of highly selective orthosteric antagonists at the M 4 mAChR subtype, although some compounds such as tropicamide (23, 24) and PD 102807 (25, 26) are often referred to as selective M 4 antagonists. However, the selectivity of tropicamide for M 4 subtype has not been confirmed in the subsequent reports (27 -29) . In the present study, PD 102807 behaved as a rather weak antagonist with micromolar order IC 50 values, and these results apparently exclude the involvement of M 4 mAChRs, considering the reported pK B value of 7.40 at cloned human M 4 mAChRs in CHO cells (26) . In the report of Chapman et al. (4) , however, the similar discrepancies were found as to the antagonistic effects of compound 28, a benzoxazine derivative synthesized subsequent to PD 102807 (5). The K B values of compound 28 determined by [ 35 S]GTPgS binding assay in mouse and rat striatal membranes (pK B = 7.11 and 7.12, respectively) were substantially less potent than the reported K i value determined by receptor binding assay for cloned human M 4 mAChRs in CHO cells (pK i = 9.0) (5) and also than that determined by themselves (pK i = 7.8). Further studies are needed as to the antagonistic properties of these benzoxazine derivatives at native mAChRs. Compared to the conventional orthosteric mAChR antagonists described above, some toxins isolated from the mamba snake venoms show a truly high selectivity to one of the five mAChR subtypes (8) . For the M 4 mAChR subtype, MT3 shows high affinity with a pK i value of 8.70, as compared to much lower affinities to the other mAChRs (pK i = 7.11 and < 6.0 for M 1 mAChR and the others, respectively) (30) . On the other hand, MT7 is a highly potent and selective antagonist for the M 1 mAChR subtype (31, 32) . In the present study, the increase in specific [
35 S]GTPgS binding elicited by 100 mM CCh was inhibited by MT3 at the highest concentration investigated (1 mM), but not by the other toxins. As shown in the inset of Fig. 6 , the inhibitory manner of MT3 in the present study was inconsistent with the typical competitive antagonism shown in the mAChRmediated adenylate cyclase inhibition assay in rat striatal (33) (36) . Among them, VU 10010 is particularly useful in investigations of M 4 mAChRs because this compound has been shown to act as a highly selective allosteric potentiator at the M 4 subtype with no activity at any other mAChR subtypes (9) . In the present study, VU 10010 potentiated the effects of CCh, by leftward shifting of the concentration-response curve as well as by enhancing the maximal response. These bimodal effects of VU 10010 are consistent with the previous functional study using CHO (12) , these results imply that the mAChRs and 5-HT 1A receptors are coupled to distinct pools of G i/o proteins. These results are consistent with our previous data on the interaction between several GPCRs (i.e., 5-HT 1A , GABA B , dopamine D 2 , adenosine A 1 , and pirenzepine-insensitive mAChRs) and their coupled G-proteins assessed by agonist-induced high-affinity GTPase activity in rat brain membranes (42 -44) . Humbert-Claude et al. (45) also reported the lack of interactions between histamine H 3 receptor-and dopamine D 2 receptor-mediated [ 35 S]GTPgS binding in rat striatum. In the case of the receptors coupled with G i/o , there may be compartmentalization that limits the free access of the receptors to the full complement of G-proteins (46) . Alternatively, the additive effects may be explained by the stoichiometric ratio between the receptors and G-proteins under the collision coupling model (47) . According to the theory by Brinkerhoff et al. (47) , the % competitive is calculated to be 74.9% for both receptors, indicating one-fourth of 5-HT 1A receptors and mAChRs share the common G i/o proteins. Whatever the underlying molecular mechanisms, these results are in marked contrast to the complete competition of G q proteins by M 1 mAChRs and 5-HT 2A receptors in rat cerebral cortical membranes revealed by antibody-capture SPA/[ 35 S]GTPgS binding using anti-Ga q antibody (48) and immunoprecipitation (49) . Further investigations are necessary to reveal the implications of these phenomena in brain functions controlled by the GPCR-mediated signal transductions.
In conclusion, the present study describes the pharmacological profile of mAChR-mediated [ 35 S]GTPgS binding determined by the conventional filtration assay in rat cerebral cortical, hippocampal, and striatal membranes in detail. All of the data using mAChR ligands, muscarinic toxins, and allosteric modulators support the notion that M 4 mAChR coupled to G i/o is the principal mediator of the response, although minor contribution of M 2 mAChR is not completely ruled out. In addition, several issues have been raised that need to be addressed, e.g., possible involvement of other GPCRs than mAChRs in the effects of xanomeline and N-desmethylclozapine, the properties of tropicamide and PD 102807 as selective M 4 mAChR antagonists, the partial agonistic effect of J 104129 in the hippocampus, the unusual inhibitory manner of MT3, and the apparent lack of allosteric effects of thiochrome and brucine N-oxide. Muscarinic agonist-stimulated [ 35 S]GTPgS binding in the membranes prepared from postmortem human brains have been utilized to unravel the pathological grounds for Alzheimer's disease (50, 51) , schizophrenia (52) , and mood disorders (53) . We intend to adapt the method described in the present study to postmortem human brains to investigate possible alterations in mAChR/G i/o interaction in mental disorders in the future.
